πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 61 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10966931

Controlled release dosage forms for high dose, water soluble and hygroscopic drug substanc

Jazz Pharmaceuticals, Inc. Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10959956

Controlled release dosage forms for high dose, water soluble and hygroscopic drug substanc

Jazz Pharmaceuticals, Inc. Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10960016

Capsules containing high doses of krill phospholipids

AKER BIOMARINE ANTARCTIC AS Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10912751

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of t

Esperion Therapeutics, Inc. Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10849911

Low dose compositions of Aramachol salts

GALMED RESEARCH AND DEVELOPMENT LTD Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10842814

Use of low dose arsenic for preserving genomic integrity

The Board of Regents of the University of Texas System Β· Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10813885

Controlled release dosage forms for high dose, water soluble and hygroscopic drug substanc

Jazz Pharmaceuticals, Inc. Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758488

Controlled release dosage forms for high dose, water soluble and hygroscopic drug substanc

Jazz Pharmaceuticals, Inc. Β· Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10751383

Doses and methods for administering telavancin

Cumberland Pharmaceuticals Inc. Β· Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10722478

Methods and compositions for treating fatigue associated with disordered sleep using very

TONIX PHARMA LIMITED Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10668015

Unit aerosol doses for anticoagulation

The Regents of the University of California Β· Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434114

Methods of treating a bacterial infection using a fixed-dose pharmaceutical composition co

RedHill Biopharma Ltd. Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391152

Methods of using a fixed dose of a clotting factor

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10335460

IL-15 and IL-15RΞ± heterodimer dose escalation regimens for treating conditions

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10300027

Effective sensitizing dose of a gelled immunomodulating topical composition

Phio Pharmaceuticals Corp. Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10143702

Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimin

RedHill Biopharma Ltd. Β· Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9981092

Pressurised metered dose inhalers and method of manufacture

Cardiff Scintigraphics Limited Β· Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9474728

Methods and compositions for treating fatigue associated with disordered sleep using very

TONIX PHARMA LIMITED Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9463193

Individual 5-fluorouracile dose optimization in folfiri treatment

INSTITUT DE CANCEROLOGIE DE L'OUEST Β· Granted Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9295659

High dose extended-release potassium citrate wax matrix tablet

UNITED LABORATORIES, INC. Β· Granted Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9198915

Methods involving aldose reductase inhibitors

The Board of Regents of the University of Texas System Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9186362

Methods involving aldose reductase inhibitors

The Board of Regents of the University of Texas System Β· Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8551997

Structural-based inhibitors of the glutathione binding site in aldose reductase, methods o

The Board of Regents of the University of Texas System Β· Granted Tue Oct 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8450299

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Teva Womans's Health, Inc. Β· Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted